EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine

Toufik Abdul-Rahman, Ranferi Eduardo Herrera-Calderón, Nicholas Aderinto, Mrinmoy Kundu, Andrew Awuah Wireko, Favour Tope Adebusoye, Olabode Ekerin, Lukman Lawal, Nikitina Iryna Mykolaivna, Athanasios Alexiou, Majed N Almashjary, Asma Perveen und 1 weitere

Journal of Integrative Neuroscience · 2024

DOI: 10.31083/j.jin2304080 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Integrative Neuroscience, 2024. Verfasst von Toufik Abdul-Rahman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Institute, Sumy State University, 40007 Sumy, Ukraine. Hauptthemen laut MEDLINE: Antipsychotic Agents, Clozapine, Hallucinations, Parkinson Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional Fund Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, including hallucinations. The use of antipsychotic medications is a common strategy to manage hallucinations associated with Parkinson’s disease psychosis (PDP). However, careful consideration is necessary when selecting the most appropriate drug due to the potential risks associated with the available treatment options. Atypical antipsychotics (AAPs), such as Pimavanserin and Clozapine, have effectively controlled PDP symptoms. On the contrary, the support for utilizing quetiapine is not as substantial as other antipsychotics because research studies specifically investigating its application are still emerging and relatively recent. The broad mechanisms of action of AAPs, involving dopamine and serotonin receptors, provide improved outcomes and fewer side effects than typical antipsychotics. Conversely, other antipsychotics, including risperidone, olanzapine, aripiprazole, ziprasidone, and lurasidone, have been found to worsen motor symptoms and are generally not recommended for PDP. While AAPs offer favorable benefits, they are associated with specific adverse effects. Extrapyramidal symptoms, somnolence, hypotension, constipation, and cognitive impairment are commonly observed with AAP use. Clozapine, in particular, carries a risk of agranulocytosis, necessitating close monitoring of blood counts. Pimavanserin, a selective serotonin inverse agonist, avoids receptor-related side effects but has been linked to corrected QT (QTc) interval prolongation, while quetiapine has been reported to be associated with an increased risk of mortality. This review aims to analyze the benefits, risks, and mechanisms of action of antipsychotic medications to assist clinicians in making informed decisions and enhance patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsClozapineHallucinationsParkinson DiseasePiperidinesQuetiapine FumarateHumansUrea

Stichwörter der Autor:innen

Parkinson's diseaseantipsychoticshallucinationsneurodegenerative disorders

Substanzen

Antipsychotic AgentsClozapinepimavanserinPiperidinesQuetiapine FumarateUrea

Autor:innen und Institutionen

  • Medical Institute, Sumy State University, 40007 Sumy, Ukraine.
  • Center for Research in Health Sciences (CICSA), Faculty of Medicine, Anahuac University North Campus, 52786 Huixquilucan, Mexico.
  • Department of Medicine and Surgery, Ladoke Akintola University of Technology, 210101 Ogbomoso, Nigeria.
  • Department of General Medicine, Institute of Medical Sciences and SUM Hospital, 751003 Bhubaneswar, India.
  • School of Public Health, University of Port Harcourt, 500004 Port Harcourt, Nigeria.
  • Faculty of Clinical Sciences, University of Ilorin, 240003 Ilorin, Nigeria.

Förderung

  • Institutional Fund Projects

Zitieren

APA

Abdul-Rahman, T., Herrera-Calderón, R. E., Aderinto, N., Kundu, M., Wireko, A. A., Adebusoye, F. T., Ekerin, O., Lawal, L., Mykolaivna, N. I., Alexiou, A., Almashjary, M. N., Perveen, A., & Ashraf, G. M. (2024). Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine. Journal of Integrative Neuroscience. https://doi.org/10.31083/j.jin2304080

Vancouver

Abdul-Rahman T, Herrera-Calderón RE, Aderinto N, Kundu M, Wireko AA, Adebusoye FT, et al. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine. Journal of Integrative Neuroscience. 2024. doi:10.31083/j.jin2304080

BibTeX
@article{AbdulRahman2024,
  author = {Abdul-Rahman, Toufik and Herrera-Calderón, Ranferi Eduardo and Aderinto, Nicholas and Kundu, Mrinmoy and Wireko, Andrew Awuah and Adebusoye, Favour Tope and Ekerin, Olabode and Lawal, Lukman and Mykolaivna, Nikitina Iryna and Alexiou, Athanasios and Almashjary, Majed N and Perveen, Asma and Ashraf, Ghulam Md},
  title = {Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine},
  journal = {Journal of Integrative Neuroscience},
  year = {2024},
  doi = {10.31083/j.jin2304080}
}
Kostenlos starten →